医学
糖尿病足
富血小板血浆
血小板
不利影响
糖尿病足溃疡
安慰剂
截肢
糖尿病
伤口愈合
前瞻性队列研究
临床试验
外科
内科学
胃肠病学
病理
替代医学
内分泌学
作者
Hussam Alhawari,Hanan Jafar,Mohammad Al Soudi,Lena Abu Ameereh,Maram Fawaris,Mohanad Saleh,Safwan Aladwan,Nidal Younes,Abdalla Awidi
摘要
Abstract Diabetic foot ulcer (DFU) is a major cause of morbidity, non‐traumatic lower limb amputation in diabetic patients and a high‐cost burden on the healthcare system. New therapeutic products are increasingly tested. Platelet‐rich plasma (PRP) and human platelet lysate (hPL) are reported to be useful. This trial was conducted to test whether the healing effect of hPL in chronic DFU was due to plasma or platelet lysates in a prospective double‐blind design. Autologous PRP was obtained from citrated blood, lysed, and used as drug 1 (active product). The platelet‐poor plasma (PPP) was used as a drug 2 (placebo). Ten patients were enrolled in arm 1 and 9 in arm 2. The drugs were injected perilesionally every 2 weeks for a total of sixinjections. Adverse events were recorded until Week 14. The DFUs were scored per the Texas and Wegner systems. No patient showed any major adverse events. Some reported local pain post‐injection. Wound healing was achieved in the hPL group in 9/10 of patients at a mean of 35.1 days. In the PPP group, no patient had healed by Day 84. The difference was statistically significant at P < 0.00001. We conclude that autologous hPL is safe and highly effective in healing chronic DFU and is superior to autologous PPP.
科研通智能强力驱动
Strongly Powered by AbleSci AI